KOSPI large cap
SK Biopharmaceuticals
A pharma company developing central-nervous-system drugs, directly selling its self-developed epilepsy drug cenobamate in the U.S. KOSPI large-cap constituent. Baseline node ahead of value-chain research; promoted to a full node once AI question demand is observed.
326030.KS Updated Jul 11, 2026 2 AI consumers· 1 recurring
Annual return · 2026-07-10'21-47.7%'22-4.4%'23+28.3%'24+17.3%'25+8.2%YTD-30.2%
Money in ▸·
SK Biopharmaceuticals
▸ Money out·
Financials & Segments
- Segments · Epilepsy drug (cenobamate) · Royalties/others
Revenue from
No refined links yet.
Pays to
No refined links yet.